Cyclophosphamide
- Generic Name
- Cyclophosphamide
- Brand Names
- Procytox
- Drug Type
- Small Molecule
- Chemical Formula
- C7H15Cl2N2O2P
- CAS Number
- 50-18-0
- Unique Ingredient Identifier
- 6UXW23996M
- Background
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
- Indication
Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma
- Associated Therapies
- -
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Low-Grade Non-Hodgkin's Lymphoma
Phase 3
Completed
- Conditions
- Stage III Grade 1 Follicular LymphomaStage III Grade 2 Follicular LymphomaStage III Grade 3 Follicular LymphomaStage III Small Lymphocytic LymphomaStage IV Grade 1 Follicular LymphomaStage IV Grade 2 Follicular LymphomaStage IV Grade 3 Follicular LymphomaStage IV Small Lymphocytic Lymphoma
- Interventions
- Drug: cyclophosphamideBiological: rituximabDrug: fludarabine phosphateDrug: vincristine sulfateOther: laboratory biomarker analysisDrug: prednisone
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-02-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 515
- Registration Number
- NCT00003204
- Locations
- 🇺🇸
Eastern Cooperative Oncology Group, Boston, Massachusetts, United States
Comparison of Chemotherapy Regimens in Treating Children With Relapsed or Progressive Rhabdomyosarcoma
Phase 2
Completed
- Conditions
- Alveolar Childhood RhabdomyosarcomaEmbryonal Childhood RhabdomyosarcomaEmbryonal-botryoid Childhood RhabdomyosarcomaPreviously Treated Childhood RhabdomyosarcomaRecurrent Childhood Rhabdomyosarcoma
- Interventions
- Drug: vincristine sulfateDrug: irinotecan hydrochlorideDrug: cyclophosphamideDrug: doxorubicin hydrochlorideDrug: ifosfamideDrug: etoposideDrug: tirapazamineBiological: filgrastimBiological: sargramostimOther: pharmacological studyOther: pharmacogenomic studiesOther: laboratory biomarker analysis
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 150
- Registration Number
- NCT00025363
- Locations
- 🇺🇸
Children's Oncology Group, Arcadia, California, United States
Oblimersen Plus Combination Chemotherapy and Dexrazoxane in Treating Children and Adolescents With Relapsed or Refractory Solid Tumors
Phase 1
Completed
- Conditions
- Cardiac ToxicityUnspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- Biological: oblimersen sodiumDrug: dexrazoxane hydrochlorideDrug: doxorubicin hydrochlorideDrug: cyclophosphamideBiological: filgrastimOther: laboratory biomarker analysisOther: pharmacological study
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 15
- Registration Number
- NCT00039481
- Locations
- 🇺🇸
Children's Oncology Group, Arcadia, California, United States
Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Not Applicable
Completed
- Conditions
- T-cell Childhood Acute Lymphoblastic LeukemiaUntreated Childhood Acute Lymphoblastic Leukemia
- Interventions
- Drug: prednisoneDrug: vincristine sulfateDrug: daunorubicin hydrochlorideDrug: asparaginaseDrug: methotrexateDrug: cyclophosphamideDrug: cytarabineDrug: mercaptopurineDrug: leucovorin calciumDrug: dexamethasoneDrug: doxorubicin hydrochlorideDrug: thioguanineRadiation: radiation therapyDrug: pegaspargaseOther: pharmacological studyDrug: nelarabineOther: laboratory biomarker analysis
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 100
- Registration Number
- NCT00016302
- Locations
- 🇺🇸
Children's Oncology Group, Arcadia, California, United States
Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Phase 3
Completed
- Conditions
- Childhood Acute Erythroleukemia (M6)Childhood Acute Megakaryocytic Leukemia (M7)Childhood Acute Monoblastic Leukemia (M5a)Childhood Acute Monocytic Leukemia (M5b)Childhood Acute Myeloblastic Leukemia With Maturation (M2)Childhood Acute Myeloblastic Leukemia Without Maturation (M1)Childhood Acute Myelomonocytic Leukemia (M4)Childhood Myelodysplastic SyndromesChronic Myelomonocytic Leukemiade Novo Myelodysplastic Syndromes
- Interventions
- Drug: daunorubicin hydrochlorideDrug: asparaginaseDrug: therapeutic hydrocortisoneRadiation: 3-dimensional conformal radiation therapyDrug: fludarabine phosphateProcedure: allogeneic bone marrow transplantationBiological: filgrastimDrug: cytarabineDrug: idarubicinDrug: dexamethasoneBiological: aldesleukinDrug: thioguanineDrug: etoposideDrug: methotrexateDrug: cyclophosphamideDrug: busulfan
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 880
- Registration Number
- NCT00002798
- Locations
- 🇺🇸
Children's Oncology Group, Arcadia, California, United States
Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma
Early Phase 1
Completed
- Conditions
- Contiguous Stage II Adult Diffuse Large Cell LymphomaContiguous Stage II Adult Diffuse Small Cleaved Cell LymphomaContiguous Stage II Grade 1 Follicular LymphomaContiguous Stage II Grade 2 Follicular LymphomaContiguous Stage II Grade 3 Follicular LymphomaContiguous Stage II Mantle Cell LymphomaContiguous Stage II Marginal Zone LymphomaContiguous Stage II Small Lymphocytic LymphomaExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueNoncontiguous Stage II Adult Diffuse Large Cell Lymphoma
- Interventions
- Biological: rituximabDrug: cyclophosphamideBiological: filgrastimRadiation: yttrium Y 90 ibritumomab tiuxetanProcedure: peripheral blood stem cell transplantation
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 30
- Registration Number
- NCT00017381
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Children With Acute Lymphoblastic Leukemia
Phase 3
Completed
- Conditions
- Recurrent Childhood Acute Lymphoblastic LeukemiaChildhood Acute Lymphoblastic Leukemia in Remission
- Interventions
- Biological: filgrastimDrug: asparaginaseDrug: cyclophosphamideDrug: cyclosporineDrug: cytarabineDrug: daunorubicin hydrochlorideDrug: dexamethasoneDrug: etoposideDrug: ifosfamideDrug: imatinib mesylateDrug: leucovorin calciumDrug: mercaptopurine tabletDrug: methotrexateDrug: pegaspargaseDrug: vincristine sulfateProcedure: allogeneic bone marrow transplantationProcedure: peripheral blood stem cell transplantationProcedure: umbilical cord blood transplantationRadiation: radiation therapy
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-02-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 220
- Registration Number
- NCT00022737
- Locations
- 🇺🇸
Children's Oncology Group, Arcadia, California, United States
Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer
Phase 3
Completed
- Conditions
- Breast AdenocarcinomaStage IA Breast Cancer AJCC v7Stage IIB Breast Cancer AJCC v6 and v7Stage IIIA Breast Cancer AJCC v7HER2 Positive Breast CarcinomaStage IB Breast Cancer AJCC v7Stage IIA Breast Cancer AJCC v6 and v7
- Interventions
- Drug: Aromatase Inhibition TherapyDrug: CyclophosphamideDrug: Doxorubicin HydrochlorideOther: Laboratory Biomarker AnalysisDrug: PaclitaxelDrug: Tamoxifen CitrateBiological: Trastuzumab
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2020-08-14
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 3436
- Registration Number
- NCT00005970
- Locations
- 🇺🇸
University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸University of Vermont and State Agricultural College, Burlington, Vermont, United States
Chemotherapy, Imatinib Mesylate, and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Phase 2
Completed
- Conditions
- Adult Acute Lymphoblastic Leukemia in Remission
- Interventions
- Drug: imatinib mesylateDrug: methotrexateDrug: vincristine sulfateDrug: leucovorin calciumProcedure: peripheral blood stem cell transplantationProcedure: autologous hematopoietic stem cell transplantationProcedure: allogeneic hematopoietic stem cell transplantationRadiation: total-body irradiationDrug: tacrolimusBiological: filgrastimDrug: etoposideDrug: cyclophosphamideDrug: cytarabineOther: laboratory biomarker analysis
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-11-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 58
- Registration Number
- NCT00039377
- Locations
- 🇺🇸
Great Falls Clinic, Great Falls, Montana, United States
🇺🇸Mason District Hospital, Havana, Illinois, United States
🇺🇸Berdeaux, Donald MD (UIA Investigator), Great Falls, Montana, United States
Combination Chemotherapy and Rituximab in Treating Patients With HIV-Associated Stage I, Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma
Phase 2
Completed
- Conditions
- AIDS-related Diffuse Large Cell LymphomaAIDS-related Immunoblastic Large Cell LymphomaAIDS-related Peripheral/Systemic LymphomaAIDS-related Small Noncleaved Cell Lymphoma
- Interventions
- Biological: rituximabDrug: etoposideDrug: doxorubicin hydrochlorideDrug: vincristine sulfateDrug: prednisoneDrug: cyclophosphamideOther: laboratory biomarker analysis
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-05-14
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 106
- Registration Number
- NCT00049036
- Locations
- 🇺🇸
AIDS - Associated Malignancies Clinical Trials Consortium, Rockville, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath